Clinical Trial Update: Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability trial comparing V114 to Prevnar for pneumococcal infection indications has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar (pneumococcal conjugate vaccine)
• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 1 | Status: COMPLETED | Results posted: 2019-03-18